These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2213832)

  • 1. Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
    Maryanoff BE; Vaught JL; Shank RP; McComsey DF; Costanzo MJ; Nortey SO
    J Med Chem; 1990 Oct; 33(10):2793-7. PubMed ID: 2213832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
    Maryanoff BE; McComsey DF; Gardocki JF; Shank RP; Costanzo MJ; Nortey SO; Schneider CR; Setler PE
    J Med Chem; 1987 Aug; 30(8):1433-54. PubMed ID: 3039136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin.
    Maryanoff BE; McComsey DF; Castanzo MJ; Setler PE; Gardocki JF; Shank RP; Schneider CR
    J Med Chem; 1984 Aug; 27(8):943-6. PubMed ID: 6747993
    [No Abstract]   [Full Text] [Related]  

  • 4. Preclinical evaluation of McN-5707 as a potential antidepressant.
    Shank RP; Gardocki JF; Schneider CR; Vaught JL; Setler PE; Maryanoff BE; McComsey DF
    J Pharmacol Exp Ther; 1987 Jul; 242(1):74-84. PubMed ID: 3039115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pyrroloisoquinoline enantiomers ((+)- and (-)-McN-5652-Z) on behavioral and pharmacological serotonergic mechanisms in rats.
    Smith DF; Jensen PN; Poulsen SH; Mikkelsen EO; Elbaz E; Glaser R
    Eur J Pharmacol; 1991 Apr; 196(1):85-92. PubMed ID: 1831423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
    Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
    J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake.
    Bøgesø KP; Christensen AV; Hyttel J; Liljefors T
    J Med Chem; 1985 Dec; 28(12):1817-28. PubMed ID: 2999402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antidepressant activity of 4-aryltetrahydrothieno[2,3-c]pyridine derivatives.
    Schneider CS; Weber KH; Daniel H; Bechtel WD; Boeke-Kuhn K
    J Med Chem; 1984 Sep; 27(9):1150-5. PubMed ID: 6471069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z.
    Suehiro M; Scheffel U; Dannals RF; Ravert HT; Ricaurte GA; Wagner HN
    J Nucl Med; 1993 Jan; 34(1):120-7. PubMed ID: 8418252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. McN-5652: a highly potent inhibitor of serotonin uptake.
    Shank RP; Vaught JL; Pelley KA; Setler PE; McComsey DF; Maryanoff BE
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1032-8. PubMed ID: 2905001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and enantioselectivity of optically active 1- and 3-substituted 4-phenyl-1,2,3,4-tetrahydroisoquinolin-4-ols and related compounds as norepinephrine potentiators.
    Kihara M; Ikeuchi M; Adachi S; Nagao Y; Moritoki H; Yamaguchi M; Taira Z
    Chem Pharm Bull (Tokyo); 1995 Sep; 43(9):1543-6. PubMed ID: 7586079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, antiulcer and antidepressive activity of 4-(4-halophenyl)-2-phenyl-1,2,3,4-tetrahydroisoquinolines.
    Mondeshka DM; Angelova IG; Tancheva CN; Ivanov CB; Daleva LD; Ivanova NS
    Farmaco; 1994; 49(7-8):475-80. PubMed ID: 7945712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further structurally constrained analogues of cis-(6-benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters.
    Kolhatkar R; Cook CD; Ghorai SK; Deschamps J; Beardsley PM; Reith ME; Dutta AK
    J Med Chem; 2004 Oct; 47(21):5101-13. PubMed ID: 15456254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.
    Fevig JM; Feng J; Rossi KA; Miller KJ; Wu G; Hung CP; Ung T; Malmstrom SE; Zhang G; Keim WJ; Cullen MJ; Rohrbach KW; Qu Q; Gan J; Pelleymounter MA; Robl JA
    Bioorg Med Chem Lett; 2013 Jan; 23(1):330-5. PubMed ID: 23177783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
    Hou J; Xing Y; Zuo D; Wu Y; Tian J; Meng Q; Yang M
    Physiol Behav; 2015 Jan; 138():141-9. PubMed ID: 25447484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline, and serotonin.
    Hyttel J; Larsen JJ
    J Neurochem; 1985 May; 44(5):1615-22. PubMed ID: 2580950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues.
    Johnson MP; Conarty PF; Nichols DE
    Eur J Pharmacol; 1991 Jul; 200(1):9-16. PubMed ID: 1685125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
    van Vliet LA; Rodenhuis N; Dijkstra D; Wikström H; Pugsley TA; Serpa KA; Meltzer LT; Heffner TG; Wise LD; Lajiness ME; Huff RM; Svensson K; Sundell S; Lundmark M
    J Med Chem; 2000 Jul; 43(15):2871-82. PubMed ID: 10956195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex.
    Kihara T; Ikeda M
    J Pharmacol Exp Ther; 1995 Jan; 272(1):177-83. PubMed ID: 7815331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.